# Ipamorelin Dosage: What the Studies Used (Research Context Only) > Ipamorelin dosage in research context: the doses, routes, and half-life used in studies — never a human recommendation. Plus reconstitution notes and comparisons. Species, dose, route, half-life. Described from the literature. Never a human protocol. ## Read this first This page describes ipamorelin dosage the only honest way a research zine can: by reporting what was given to which animal, at what dose, by what route, in published studies. It is not a protocol. There is no "recommended dose" here, and there shouldn't be one anywhere — ipamorelin is not an approved medicine and its one human efficacy trial failed [3]. Why the caution isn't just lawyer-speak: the doses below are mostly intravenous, given to rats, swine, ferrets, or surgical patients in a hospital, in studies measuring biology — not the subcutaneous self-injection routines you'll find in forums. Those community routines have **no** peer-reviewed human dosing basis. Treat everything here as a record of what researchers did, not a how-to. We cover the half-life, the routes studied, the reconstitution chatter, and how ipamorelin lines up against sermorelin and tesamorelin. ## Doses used in published studies Here is the actual range from the literature — third person, study-attributed, every figure cited: - **Human PK/PD study:** 4.21 to 140.45 nmol/kg IV over 15 minutes, single doses, in healthy men [2]. - **Human Phase 2 ileus RCT:** 0.03 mg/kg IV twice daily for up to 7 days, in bowel-resection patients [3]. - **Rat bone-growth study:** 18, 90, and 450 micrograms/day subcutaneous, divided three times daily, over 15 days [4]. - **Ferret cachexia study (2024):** 1 to 3 mg/kg intraperitoneal [5]. Notice the pattern: the human work is intravenous and short, the animal work uses routes (intraperitoneal) and doses you'd never extrapolate to a person. The popular subcutaneous "stack" protocols that pair ipamorelin with CJC-1295 are **anecdotal** — community-derived, not trial-based — and we describe them as exactly that, with no numbers attached [3]. ## Half-life and how long it lingers In healthy men, ipamorelin's terminal half-life is about **2 hours** by the IV route, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The GH response it triggers isn't a plateau — it's a single discrete pulse that peaks around 40 minutes (0.67 hours) after dosing and then subsides [2]. In rats, plasma clearance runs roughly five-fold lower than GHRP-6. The practical read: the peptide itself clears fast, and its biological footprint is a brief, sharp GH pulse rather than a sustained elevation. ## Routes that have actually been studied The literature covers several routes, and they're not interchangeable [2]. Intravenous is the route of the human PK and clinical-trial work and rodent efficacy studies. Subcutaneous is the dominant route in rodent bone and body-composition studies — and the dominant route in community use, though without human safety data behind it. Intranasal has been characterized in rodents at roughly 20% bioavailability. Intraperitoneal appears in rodent and ferret efficacy work [5]. Plain ipamorelin is **not** orally bioavailable — oral delivery has only been engineered into ipamorelin-derived analogs (around 10% in dogs), which is its own page: see [ipamorelin oral](/oral). ## How to reconstitute cjc-1295 ipamorelin 5mg This is a top search, so here's the honest framing rather than an instruction. As a lyophilized (freeze-dried) peptide, ipamorelin is supplied as powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw, so a reconstituted research solution is typically kept refrigerated. Those are general peptide-handling observations from the research-supply literature — not a clinical preparation instruction, and not a measured-volume protocol for human use. There is no approved 5mg human product to reconstitute; combination "5mg" vials are gray-market research material, and the combination has no controlled human dosing basis [3]. We describe the handling; we don't write you a mixing recipe. ## How much cjc-1295 ipamorelin should i take We won't answer this as a dose, because there isn't a legitimate one to give. There is no approved human dose of ipamorelin or of the CJC-1295 + ipamorelin combination, and no controlled trial of the combination established a dose for any outcome [3]. The amounts circulating in community protocols are self-experimentation, not medicine — they carry no peer-reviewed human dosing basis and we won't reproduce them [3]. What the published record *can* tell you is what was given in studies (the IV and animal doses above) and that ipamorelin's solo human efficacy trial failed [3]. If a vendor or clinic hands you a confident milligram-by-bodyweight number, understand that it's extrapolated from single-agent pharmacology and forum lore, not from a trial of the thing you'd actually be taking. ## Ipamorelin vs sermorelin **Ipamorelin vs sermorelin** is a comparison of two different receptor mechanisms, not two flavors of the same thing. Ipamorelin is a GHRP — it acts on the ghrelin / GHS-R1a receptor to fire a GH pulse, and does so without raising cortisol or prolactin [1]. Sermorelin is a GHRH analog — it acts on the GHRH receptor to raise GH-releasing drive. That's precisely why the two get paired rather than swapped: complementary mechanisms. On regulatory standing they also differ sharply, and that's this site's lens — ipamorelin was never approved and was dropped from the 503A compounding list in 2024 [13]; sermorelin has its own distinct regulatory history. We don't make a head-to-head efficacy claim, because no controlled trial pits them against each other for a wellness outcome. ## Ipamorelin vs tesamorelin **Ipamorelin vs tesamorelin** is the starkest regulatory contrast in this whole class — which is the point worth surfacing. Tesamorelin is a GHRH analog that *is* FDA-approved, but for one narrow indication only: reducing excess visceral abdominal fat in HIV-associated lipodystrophy. Ipamorelin is a GHRP that is approved for nothing, anywhere, and was pulled from the 503A compounding list in 2024 [13]. Mechanistically they're different doors to the same GH pulse — tesamorelin through the GHRH receptor, ipamorelin through the ghrelin receptor [1]. The marketing that lumps them as interchangeable "GH peptides" glosses over the fact that one cleared trials for a specific use and one failed its only published efficacy trial [3]. --- It says shop; it sells nothing — just a zine pinning ipamorelin's never-approved, pulled-from-the-503A-list, banned-in-sport record next to what the studies actually measured.